REVIVA PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

11 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

30 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

20 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

16 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

14 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

30 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

25 Sep 2023 05:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

07 Sep 2023 05:00:00 By Nasdaq GlobeNewswire